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Abstract: Purpose: High levels of high density lipoprotein (HDL) cholesterol are associated with a decreased risk of 
coronary heart disease (CHD). Subjects with high levels of HDL cholesterol (>70 mg/dl; 1.79 mmol/l) as well as high  
levels of low density lipoprotein (LDL) cholesterol, could represent a group with longevity syndrome (LS). Since HDL 
particles are influenced by cholesteryl ester transfer protein (CETP) activity, it is worth studying the CETP polymor-
phism. The aim of the study was to detect whether 2 genetic variants of the CETP are associated with the LS.  
Subjects and Methods: The study population consisted of 136 unrelated men and women with no personal and family  
history of CHD; 69 met the criteria for LS and 67 did not meet these criteria and had “normal” HDL cholesterol (>40 and 
<70 mg/dl; >1.03 and <1.79 mmol/l). All patients were genotyped for the TaqIB and I405V polymorphisms. 
Results: The B2 allele frequency of TaqIB polymorphism was higher in the LS in comparison with the non-LS group 
(p=0.03) whereas B1 allele frequency was higher in the non-LS group (p=0.03). 
Conclusions: Gene polymorphisms could help decide whether individuals who have increased levels of both LDL choles-
terol and HDL cholesterol require treatment. Some of the prerequisites could include that subjects with LS should not only 
have very high levels of HDL cholesterol but also favorable gene polymorphisms. However, further investigations with a 
larger sample and including other gene polymorphisms, are needed. 
Keywords:  Coronary  heart  disease,  high  density  lipoprotein-cholesterol,  longevity  syndrome,  TaqIB  and  I405V  polymor-
phisms.  
INTRODUCTION 
  The hypothesis that low high density lipoprotein (HDL) 
cholesterol concentrations are associated with a greater risk 
of coronary heart disease (CHD) has been raised since the 
1950s [1]. More than 50 years on, following a number of 
prospective  studies  [2-7],  HDL  cholesterol  is  now  estab-
lished as an independent risk factor for CHD [8]. However, 
there may also be a positive association of HDL cholesterol 
levels with increased CHD risk [9]. 
  Based on clinical evidence that elevated HDL cholesterol 
levels reduce CHD risk it is plausible that this characteristic 
could  also  be  associated  with  longer  life  expectancy  [10]. 
This  hypothesis  is  further  supported  by  the  fact  that  high 
HDL cholesterol levels are often observed in healthy elderly 
persons aged >85 years [10, 11]. The levels of HDL choles-
terol  are  influenced  by  various  environmental  and  genetic  
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factors. Family and twin studies have estimated that the heri-
tability of HDL cholesterol levels varies from 35 to 66% [10, 
12, 13]. A degree of heritability has been also reported in 
longevity.  Siblings  of  centenarians  have  an  8-  to  17-fold 
higher  probability  of  living  past  the  age  of  100  years,  
accounting  for  only  approximately  1  of  10000  individuals  
in  the  general  population  [14].  Several  genes  can  affect  
HDL metabolism; among these are those related to choles-
teryl ester transfer protein (CETP). A number of polymor-
phisms and rare variants in the human CETP gene have been 
identified. Two of the common polymorphisms, TaqIB and 
I405V, are  associated with plasma HDL  cholesterol  levels 
[15-17].  
  In the current study, the prevalence of very high serum 
HDL cholesterol (>70 mg/dl), in at least 2 related members 
of  a  family  plus  a  history  of  longevity  (any  living  or  de-
ceased relative >90 years old) in the family are referred to as 
longevity syndrome (LS). The occurrence of LS is very rare. 
It is very likely that subjects with LS, besides high HDL cho-
lesterol  levels,  have  additional  protective  metabolic  traits. 
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gram Adult Treatment Panel III (NCEP ATP III) guidelines 
for low-density lipoprotein (LDL) cholesterol levels [18, 19], 
the dilemma arises whether subjects with “raised” levels of 
LDL cholesterol but also with very high HDL concentration 
are still candidates for hypolipidaemic treatment. Gene po-
lymorphisms  could  help  decide  whether  individuals  who 
have increased levels of both LDL cholesterol and HDL cho-
lesterol require treatment. In line with previous work from 
our group [20], we tested the hypothesis that subjects with 
LS  may  carry  the  favorable  variants  of  the  CETP  TaqIB 
or/and  I405V  polymorphisms  compared  with  subjects  not 
meeting the criteria for LS.  
MATERIALS AND METHODOLOGY 
Study Population 
  The study population consisted of 136 unrelated men and 
women without history of CHD. They were recruited from 
the Outpatient Lipid Clinic of our hospital (Athens, Greece) 
or  self-referred  (hospital  personnel).  All  subjects  were  re-
ferred for moderate hypercholesterolaemia. In order to ex-
clude  underlying  CHD  the  study  population  underwent  a 
physical and a stress testing examination. A detailed family 
history was also obtained.  
LS Group 
  Sixty nine probands of long-lived subjects met the fol-
lowing criteria for LS (LS group). The characterization of LS 
was based on ALL of the following criteria: 1) plasma fast-
ing HDL cholesterol concentration >70 mg/dl (1.79 mmol/l), 
2) at least 1 relative with plasma HDL cholesterol concentra-
tion >70 mg/dl (1.79 mmol/l), 3) at least 1 relative (deceased 
or alive) over the age of 90 years old, and, 4) no personal or 
family history of cardiovascular disease. 
Non-LS Group 
  Sixty seven subjects served as controls (non-LS group). 
They  had  desirable  HDL  cholesterol  (>40  mg/dl  and  <70 
mg/dl;  >1.03  and  <1.79  mmol/l),  according  to  the  NCEP 
ATP III guidelines [18, 19]. They did not have any relative 
(deceased or alive) with plasma HDL cholesterol >70 mg/dl 
(1.79 mmol/l) nor any relative (deceased or alive) over the 
age  of  90  years.  This  information  was  derived  from  the 
analysis of 3 generations. 
  Both  LS  and  non-LS  groups  had  no  obesity,  diabetes 
mellitus and hypertension which are risk factors for CHD. 
Additionally, they did not suffer from stroke, cancer, demen-
tia or other age-related diseases. They were referred to our 
lipid  clinic  for  their  annual  routine  physical  examination. 
The majority of individuals (88%) from the LS group were 
referred to us for increased LDL cholesterol levels according 
to NCEP ATP III guidelines [18, 19]. The remained indi-
viduals were self-referred (hospital personnel) to the study 
for their exceptional high HDL levels. Heavy drinking, he-
patic disease, renal disease, and hypothyroidism were among 
the exclusion criteria. Hypertension was defined as systolic 
arterial blood pressure  >140 mmHg and/or diastolic blood 
pressure >90 mmHg or as current treatment with antihyper-
tensive drugs. All subjects in both groups had a body mass 
index (BMI) <30 kg/m
2. Diabetes was defined according to 
the diagnostic criteria of the World Health Organization or 
as current treatment of diabetes [21]. Only 15% of subjects 
were smokers in each group. None of the subjects was taking 
any medication. Triglycerides levels were < 150 mg/dl (1.68 
mmol/l)  in  both  groups  and  mean  LDL-cholesterol  levels 
were < 130 mg/dl (3.3 mmol/l) in non-LS group. These lev-
els  are normal  according to  the NCEP ATP III guidelines 
[18, 19]. The mean value of LDL cholesterol in LS group 
was above 160 mg/dl (4 mmol/l), which is raised according 
to the NCEP ATP III guidelines [18, 19]. 
  The  Onassis  Cardiac  Surgery  Center  ethics  committee 
approved the protocol of this study. All patients signed an 
informed consent form. 
Gene Polymorphisms  
  CETP TaqIB and I405V genotyping was performed by 
polymerase  chain  reaction  and  restriction  fragment  length 
polymorphism as previously described [22-25]. 
Biochemical Analyses 
  Plasma total cholesterol, triglycerides and HDL choles-
terol were measured using enzymatic colorimetric methods 
on a Roche Integra Biochemical analyzer with commercially 
available  kits  (Roche).  The  serum  low  density  lipoprotein 
(LDL) levels were calculated using the Friedewald formula 
[26]. 
Statistical Analysis 
  The normality of continuous variables was tested using 
the Shapiro-Wilk statistic. None of the continuous variables 
had a non-normal distribution. 
  Continuous variables are presented as mean ± standard 
deviation, while qualitative variables are presented as abso-
lute and relative frequencies. Contingency tables were con-
structed to evaluate the association between genotypes, car-
riers  and  LS.  The  statistical  evaluation  for  the  categorical 
variables was based on the calculation of the chi-square and 
Fisher’s exact criteria. Comparison of mean values between 
study groups was performed with the Student’s t-test. Esti-
mations of the multivariate association of the B2 allele with 
LS were performed by the calculation of the odds ratio (OR) 
and the corresponding confidence intervals through logistic 
regression analysis, after adjusting for age and BMI. 
  All  tests  were  two-sided  and  p-values  of  0.05  were  
considered significant. Data were analyzed using STATA™ 
(version 9.0, Stata Corporation, College Station, TX, USA). 
RESULTS 
Clinical and Laboratory Parameters  
  Clinical characteristics and laboratory parameters of the 
non-LS and LS groups are shown in Table 1. BMI was lower 
in the LS compared with non-LS group. The mean age dif-
ference between the 2 groups was 6 years. Serum total LDL 
and HDL cholesterol were higher while plasma triglyceride 
concentration  was  lower  in  LS  group  compared  with  the 
non-LS group. Moreover the LDL/HDL cholesterol ratio was 
higher  in  the  non-LS  group  and  statistically  significant  in 
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Distribution of CETP Genotypes 
  Table 2 shows the CETP genotype and allele frequencies 
in the 2 groups. No significant differences were found con-
cerning the genotype frequency of TaqIB and I405V poly-
morphisms, between the 2 groups. However, the frequency 
of B2B2 genotype in LS group was twofold higher in com-
parison  with  the  same  genotype  frequency  in  the  non-LS 
group. The B2 allele frequency was significantly higher in 
the  LS  compared  with  the  non-LS  group,  while  B1  allele 
frequency was significantly higher in the non-LS compared 
with the LS group. Concerning the I and V alleles, there was 
a trend (p=0.053) with the latter being more frequent in the 
LS group. There was no significant correlation between the 
alleles of the TaqIB or I405V polymorphism and HDL levels 
with groups. 
  Those  with  LS  had  69%  more  odds  of  having  the  B2  
allele, compared with the non-LS, adjusting for age (Table 
3). Although not significant, it should also be noted that the 
same participants had 64% more odds of having the B2 allele 
than the non-LS, adjusting for BMI (Table 3). When fully 
adjusted  for  BMI  and  age,  there  was  not  any  statistically 
significant  difference  concerning  the  frequency  of  the  Β2 
allele between LS and non-LS. When adjusted for triglyc-
erides  and  age  our  result  remained  significant.  When  
adjusted for the other lipids the significance was lost. 
DISCUSSION 
  Our subjects with LS were more frequently carriers of the 
B2 allele of the TaqIB polymorphism than healthy subjects. 
The aim of the study was to evaluate whether subjects with 
LS in the family who potentially will  live longer than the 
average  life expectancy, have favourable  CETP gene vari-
ants compared with healthy subjects. This genetic distinction 
may be important in the management of patients. 
Table 1.  Clinical Characteristics of the Non-LS and LS Group 
non-LS  LS 
   Mean  SD  Mean  SD  p 
Age (years)  56  13  49  20  0.008 
BMI (kg/m
2)  26  4  23  3  <0.001 
TC (mg/dl)  210  43  270  49  <0.001 
TG (mg/dl)  93  34  81  36  0.043 
HDL (mg/dl)  53  13  84  12  <0.001
* 
LDL (mg/dl)  128  27  168  45  <0.001 
LDL/HDL ratio  2.6  0.8  2  0.6  <0.001 
LS: longevity syndrome, BMI: body mass index, TC: total cholesterol, TG: triglycerides, HDL: high density lipoprotein cholesterol, LDL: low density lipoprotein cholesterol, SD: 
standard deviation.  
* HDL was a criterion for the selection of patients. 
To convert cholesterol from mg/dl to mmol/l divide by 38.67 and to convert triglycerides from mg/dl to mmol/l divide by 88.57. 
Table 2.  Distribution of CETP Genotype and Allele Frequencies in the 2 Groups 
  Genotype or Allele  non-LS n (%)  LS n (%) 
TaqIB  Β2Β2   13 (19)  26 (38) 
  Β1Β2   36 (54)  31 (45) 
  Β1Β1   17 (25)  12 (17) 
  Β1
a  70 (53)  55 (40) 
  Β2
a  62 (47)  83 (60) 
I405V  VV  1 (2)  5 (7) 
  IV  18 (42)  39 (56) 
  II  24 (56)  25 (36) 
  V  20 (23)  49 (35) 
  I  66 (77)  89 (64) 
CETP: cholesteryl ester transfer protein, LS: longevity syndrome. 
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  CETP may have pro- or anti-atherogenic properties de-
pending upon the lipid-metabolic setting [27]. The HDL par-
ticle  is  influenced  by  CETP  activity.  CETP  promotes  the 
exchange  of  cholesteryl  esters  for  triglycerides  between 
HDL and triglyceride-rich lipoproteins [28] Furthermore, the 
HDL  particle  is  involved  in  reverse  cholesterol  transport 
[29]. The cholesterol from extrahepatic cells is incorporated 
into  the HDL particle  and is transported  to  the  liver [29]. 
Then, the excess cholesterol is removed via cholic acids to 
the intestine [29]. Low HDL levels (<40 mg/dl) are consid-
ered as an independent risk factor for CHD [2-7]. Ordovas et 
al. suggested that increased HDL cholesterol levels resulting 
from  lower  CETP  activity  appear  to  be  associated  with  a 
lower risk of CHD in male subjects [30]. 
  There are controversial studies reporting that CETP po-
lymorphisms can be associated with either increased CHD 
risk  or  longevity  [31-35].  Also,  significant  associations  of 
the B1B1 genotype with higher plasma CETP concentration 
and/or CETP activity and lower HDL cholesterol were found 
in several  studies [30, 36, 37], but  this is not consistently 
observed [38, 39]. In our study, we did not measure CETP 
activity,  and  we  may  only  speculate  that  LS  subjects  had 
lower CETP concentration and activity since they had nor-
mal BMI [40] and normal triglyceride levels [41]. 
  The West of Scotland Coronary Prevention Study tested 
the association of CETP polymorphisms with the risk of car-
diovascular events [42]. In this study, those homozygous for 
the  B2  allele  had  a  30%  reduced  risk  of  a  cardiovascular 
event (OR 0.70, CI (95) 0.51-0.96, p=0.03) compared with 
B1 homozygotes. Furthermore, in a large population-based 
cohort, the B2 allele was associated with a less atherogenic 
LDL particle size distribution, consisting
 of decreased levels 
of  the  more  atherogenic  small  LDL  subfraction  and  in-
creased levels of the less atherogenic large LDL [43-45]. In 
the Framingham Offspring Study, the B2 allele was associ-
ated with a reduced risk of CHD in men [30], and this was 
confirmed in the Veterans Affair HDL cholesterol Interven-
tion  Trial  (VA  HIT)  [46].  In  contrast,  no  association  was 
found between any of the TaqIB genotypes and CHD in sub-
jects with a history
 of myocardial infarction in the Coronary 
and Recurrent Events Study [47] and in a cohort of healthy 
middle-aged U.S. physicians [48]. Brousseau et al. [46] re-
ported that in men with CHD and HDL deficiency (VA HIT 
study),  the  frequency  of  the  B2B2  genotype  was  reduced. 
However, there are studies suggesting that B2 allele carriers 
have higher HDL cholesterol levels than B1 allele carriers; 
paradoxically they have an increased risk for CHD [49, 50, 
22].  However,  a  meta-analysis  of  7  studies  (Physicians’ 
Health Study, Northwick Park Heart Study, Reykjavik, EC-
TIM, OPERA, EARS and the study of Arca et al), reported a 
lower cardiovascular risk in B2 compared with B1 homozy-
gotes [37]. 
  A  possible  mechanism  that  explains  the  association  of 
CETP
 genotype with CHD risk is the influence on plasma 
HDL. Kuivenhoven et al. [51] reported a strong association 
between B1 allele and low HDL
 cholesterol levels, which is 
in agreement with the results of
 others [36, 52, 53]. Moreo-
ver, our group reported a positive association between  B1 
genotype  and  postprandial  lipemia  [20].  Bruce  et  al. r e-
ported that the HDL cholesterol levels were higher in VV 
than IV and II men [54]. However, the increase in HDL cho-
lesterol was only significant in VV men with plasma triglyc-
eride > 165 mg/dl (1.85 mmol/l). In another study, the indi-
viduals  homozygous  for  the  V  allele  also  had  the  highest 
HDL cholesterol levels [55]. Opposite to the beneficial in-
fluence of homozygosity of VV, Kakko et al., found that the 
VV genotype seems  to be most harmful for men with the 
highest alcohol consumption [56]. In our study, the lack of
 
an association between the TaqIB or I405V polymorphisms 
and  HDL  cholesterol  observed  within  groups  does  not 
weaken  the  association  between  these  polymorphisms  and 
the presence of the LS. This was expected since each group 
was selected to have normal or very high HDL levels whose 
range was narrow. Therefore, analysis with a larger number 
of subjects is needed in order to assess such an association. 
  Populations with low CHD mortality rates, for example 
Eskimos,  have  high  levels  of  HDL  cholesterol  (even  with 
conjointly elevated LDL) which is similar to our study popu-
lation [57]. Additionally, subjects with familial hypobeta and 
familial hyperalphalipoproteinaemia which  are also associ-
ated with lower CHD rates, share a common characteristic,  
a  ratio  of  LDL:HDL  of  approximately  1:1.  This  ratio  
of  LDL:HDL  is  considerably  lower  than  the  usual  2.5:1  
observed in the general population [58]. In our LS group, the 
ratio was 2:1 and in non-LS group 2.7:1 which is comparable 
with other studies [20]. 
  The limitations in our study are the mean age difference 
(6 years) and the different BMI between the 2 groups. Al-
though significant, these factors can not influence the gene 
distribution of our study population.  The small number of 
our sample and the differences in lipid levels are disadvan-
tages. When adjusted for triglycerides and age the statistical 
significance of our results remained. When adjusted for the 
other lipids there was not statistical significance concerning 
the B2 allele between LS and non-LS groups. However hy-
per-HDL-cholesterolemia  and  longevity  represent  various 
pathophysiological  conditions  and  can  not  be  represented 
solely  from  the  genetic  constitution  of  an  organism,  nor 
solely  from  the  environmental  factors.  Additionally,  our 
sample although small, was not genetically heterogeneous,  
 
Table 3.  Multiple Logistic Regression of LS on the B2 Allele, after Adjusting for BMI and Age 
Dependent Variable  Explanatory Variable  Odds Ratio  95% Confidence Interval  p 
B2 allele
a  LS vs non-LS  1.643  (0.968-2.789)  0.07 
B2 allele
b  LS vs non-LS  1.687  (1.017-2.795)  0.04 
LS: longevity syndrome, BMI: body mass index. 
aAdjusted for BMI, 
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more specifically there was no population admixture, some-
thing that in past created inconsistencies to similar genetic 
association  studies.  Considering  the  existence  of  a  strong 
familial component to extreme longevity, and the fact that 
previous studies investigated longevity in families [59] or in 
a preselected population, it was not possible to find a com-
pletely  age-matched  control  group.  For  example,  siblings  
of  centenarians  have  an  8-  to  17-fold  higher  probability  
of  living  past  the  age  of  100  years,  accounting  for  only  
approximately 1 of 10000 individuals in the general popula-
tion [60]. 
  In our study, LS subjects had higher B2 allele frequency 
and  lower  triglyceride  levels  compared  with  the  non-LS 
group.  In  the  LS  group,  total  and  LDL  cholesterol  levels 
were  higher  compared  with  non-LS  individuals.  Thus,  the 
dilemma arises whether or not LS subjects should/should not 
receive  hypolipidaemic  treatment  according  to  available 
guidelines. Until more knowledge is available the manage-
ment of these individuals remains controversial. Some of the 
prerequisites could include that subjects with LS should not 
only have very high levels of HDL cholesterol but also fa-
vorable  gene  polymorphisms.  However,  further  investiga-
tions with a larger sample  and  including other gene poly-
morphisms,  are  needed.  Obviously,  prospective  studies  in 
patients with LS have their limitations.  
CONCLUSION 
  Individuals with LS had a higher B2 allele frequency of 
the TaqIB polymorphism than non-LS subjects. Gene poly-
morphisms could help decide whether individuals who have 
increased levels of both LDL cholesterol and HDL choles-
terol require treatment.  
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REFERENCES 
[1]  Barr DP, Russ EM, Eder HA. Protein-lipid relationships in human 
plasma. Am J Med 1951; 11: 480-5. 
[2]  Yaari  S,  Goldbourt,  Even-Zohar  S,  Neufeld  HN.  Associations  of 
serum high density lipoprotein and total cholesterol with total, car-
diovascular,  and cancer mortality  in  a 7-year  prospective study of 
10000 men. Lancet 1981; 1: 1011-5. 
[3]  Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipopro-
tein cholesterol and cardiovascular disease. Four prospective Ameri-
can studies. Circulation 1989; 79: 8-15. 
[4]  Gofman JW, Young W, Tandy R. Ischemic heart disease, atheroscle-
rosis, and longevity. Circulation 1966; 34: 679-97. 
[5]  Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery 
disease in non-insulin dependent diabetes mellitus: United Kingdom 
Prospective Diabetes Study (UKPDS:23). BMJ 1998; 316: 823-8. 
[6]  Assmann G, Schulte H. Relation of high-density lipoprotein choles-
terol and triglycerides to incidence of atherosclerotic coronary artery 
disease  (the  PROCAM  experience).  Prospective  Cardiovascular 
Munster Study. Am J Cardiol 1992; 70: 733-7. 
[7]  Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, 
Kannel  WB.  Incidence  of  coronary  heart  disease  and  lipoprotein  
cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-
8. 
[8]  Packard C, Saito Y. Non-HDL cholesterol as a measure of atheroscle-
rotic risk. J Atheroscler Thromb 2004; 11: 6-14. 
[9]  Nagano M, Yamashita S, Hirano K, et al. Molecular mechanisms of 
cholesteryl ester transfer protein deficiency in Japanese. J Atheroscler 
Thromb 2004; 11: 110-21. 
[10]  Arai Y,  Hirose N.  Aging and HDL metabolism  in  elderly people 
more than 100 years old. J Atheroscler Thromb 2004; 11: 246-52. 
[11]  Nikkilä M, Heikkinen J. Age Ageing 1990; 19: 119-24. 
[12]  Hunt SC, Hasstedt SJ, Kuida H, Stults BM, Hopkins PN, Williams 
RR. Genetic heritability and common environmental components of 
resting and stressed blood pressures, lipids, and body mass index in 
Utah pedigrees and twins. Am J Epidemiol 1989; 129: 625-38. 
[13]  Snieder H, van Doornen LJ, Boomsma DI. The age dependency of 
gene expression for plasma lipids, lipoproteins, and apolipoproteins. 
Am J Hum Genet 1997; 60: 638-50. 
[14]  Barzilai N, Atzmon G, Schechter C, et al. Unique lipoprotein pheno-
type  and  genotype  associated  with  exceptional  longevity.  JAMA 
2003; 290: 2030-40. 
[15]  Thompson A, Di Angelantonio E, Sarwar N, et al. Association of 
cholesteryl  ester  transfer  protein  genotypes  with  CETP  mass  and  
activity, lipid levels, and coronary risk. JAMA 2008; 299: 2777-88. 
[16]  Boekholdt SM, Thompson JF. Natural genetic variation as a tool in 
understanding the role of CETP in lipid levels and disease. J Lipid 
Res 2003; 44: 1080-93. 
[17]  Boekholdt  SM,  Kuivenhoven  JA,  Hovingh  GK,  Jukema  JW, 
Kastelein  JJ,  van  Tol  A.  CETP  gene  variation:  relation  to  lipid  
parameters and cardiovascular risk. Curr Opin Lipidol 2004; 15: 393-
8. 
[18]  Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults. Executive Summary of the Third Report of the 
National  Cholesterol  Education  Program  (NCEP)  Expert  Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97. 
[19]  National  Cholesterol  Education  Program  (NCEP)  Expert  Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in 
Adults  (Adult  Treatment  Panel  III).  Third  Report  of  the  National 
Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation,  and  Treatment  of  High  Blood  Cholesterol  in  Adults 
(Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-
421. 
[20]  Kolovou GD, Anagnostopoulou KK, Salpea KD, et al. Postprandial 
lipemia  in  postmenopausal  women  with  high  fasting  high-density 
lipoprotein cholesterol. Am J Med Sci 2006; 331(1): 10-6. 
[21]  Alberti KG, Zimmet PZ. Definition, diagnosis and classification of 
diabetes mellitus and its complications. Part 1: diagnosis and classifi-
cation of diabetes mellitus provisional report of a WHO consultation. 
Diabet Med 1998; 15: 539-53. 
[22]  Kolovou  G,  Anagnostopoulou  K,  Kostakou  P,  et  al.  Association 
between  the  TaqIB polymorphism  in  the cholesteryl  ester  transfer 
protein gene locus and postprandial plasma lipoprotein levels in het-
erozygotes for familial hypercholesterolemia. Clin Chem Lab Med 
2007; 45: 1190-8. 
[23]  Fumeron F, Betoulle D, Luc G, et al. Alcohol intake modulates the 
effect of a polymorphism of the cholesteryl ester transfer protein gene 
on plasma high density lipoprotein and the risk of myocardial infarc-
tion. J Clin Invest 1995; 96: 1664-71. 
[24]  Gudnason V, Kakko S, Nicaud V, et al. Cholesteryl ester transfer 
protein gene effect on CETP activity and plasma high-density lipo-
protein in European populations. The EARS Group. Eur J Clin Invest 
1999; 29: 116-28. 
[25]  Kolovou GD, Anagnostopoulou KK, Karyofillis P, et al. Cholesteryl 
ester transfer protein gene polymorphisms and severity of coronary 
stenosis. Clin Invest Med 2006; 29: 14-9. CETP and Longevity  The Open Cardiovascular Medicine Journal, 2010, Volume 4    19 
[26]  Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concen-
tration of the low-density lipoprotein cholesterol in plasma, without 
use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502. 
[27]  Tsai MY, Li N, Sharrett AR, et al. Associations of genetic variants  
in  ATP-binding  cassette  A1  and  cholesteryl  ester  transfer  protein  
and differences in lipoprotein subclasses in the multi-ethnic study of 
atherosclerosis. Clin Chem 2009; 55: 481-8. 
[28]  Kolovou GD, Anagnostopoulou KK, Daskalopoulou SS, Mikhailidis 
DP, Cokkinos DV. Clinical relevance of postprandial lipemia. Curr 
Med Chem 2005; 12: 1931-45. 
[29]  Lewis GF, Rader DJ. New insights into the regulation of HDL me-
tabolism and reverse cholesterol transport. Circ Res 2005; 96: 1221-
32. 
[30]  Ordovas JM, Cupples LA, Corella D, et al. Association of cholesteryl 
ester transfer protein-TaqIB polymorphism with variations in lipopro-
tein  subclasses  and  coronary  heart  disease  risk:  the  Framingham 
study. Arterioscler Thromb Vasc Biol 2000; 20: 1323-9. 
[31]  Koizumi J, Mabuchi H, Yoshimura A, et al. Deficiency of serum 
cholesteryl-ester  transfer activity  in patients  with  familial hyperal-
phalipoproteinaemia. Atherosclerosis 1985; 58:175-86. 
[32]  Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipo-
protein levels caused by a common cholesteryl-ester transfer protein 
gene mutation. N Engl J Med 1990; 323: 1234-8. 
[33]  Hirano K, Yamashita S, Nakajima N, et al. Genetic cholesteryl ester 
transfer protein deficiency is extremely frequent in the Omagari area 
of Japan; marked hyperalphalipoproteinemia caused by CETP gene 
mutation is not associated with longevity. Arterioscler Thromb Vasc 
Biol 1997; 17: 1053-9. 
[34]  Zhong S, Sharp DS, Grove JS, et al. Increased coronary heart disease 
in  Japanese-American  men  with  mutation  in  the  cholesteryl  ester 
transfer  protein  gene  despite  increased  HDL  levels.  J  Clin  Invest 
1996; 97: 2917-23. 
[35]  Hirano K, Yamashita S, Sakai N, et al. Molecular defect and athero-
genicity  in  cholesteryl  ester  transfer  protein  deficiency.  Ann N  Y 
Acad Sci 1995; 748: 599-602. 
[36]  Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a 
common variant of the cholesteryl ester transfer protein gene in the 
progression  of  coronary  atherosclerosis.  The  Regression  Growth 
Evaluation Statin Study Group. N Engl J Med 1998; 338: 86-93. 
[37]  Boekholdt SM, Sacks FM, Jukema JW, et al. Cholesteryl ester trans-
fer protein TaqIB variant, high-density lipoprotein cholesterol levels, 
cardiovascular risk, and efficacy of pravastatin treatment: individual 
patient meta-analysis of 13,677 subjects. Circulation 2005; 111: 278-
87. 
[38]  Freeman DJ, Griffin BA, Holmes AP, et al. Regulation of plasma 
HDL cholesterol and  subfraction  distribution by genetic and envi-
ronmental  factors:  associations  between  the  TaqI  B  RFLP  in  the 
CETP gene and smoking and obesity. Arterioscler Thromb 1994; 14: 
336-44. 
[39]  Goto A, Sasai K, Suzuki S, et al. Cholesteryl ester transfer protein 
and atherosclerosis in Japanese subjects: a study based on coronary 
angiography. Atherosclerosis 2001; 159: 153-63. 
[40]  Arai T, Yamashita S, Hirano K, et al. Increased plasma cholesteryl 
ester transfer protein in obese subjects. A possible mechanism for the 
reduction of serum HDL cholesterol levels in obesity. Arterioscler 
Thromb 1994; 14: 1129-36. 
[41]  Tato  F,  Vega  GL,  Grundy  SM.  Determinants  of  plasma  HDL-
cholesterol in hypertriglyceridemic patients. Role of cholesterol-ester 
transfer protein and lecithin cholesteryl acyl transferase. Arterioscler 
Thromb Vasc Biol 1997; 17: 56-63. 
[42]  Freeman DJ, Samani NJ, Wilson V, et al. A polymorphism of the 
cholesteryl ester transfer protein gene predicts cardiovascular events 
in non-smokers in the West of Scotland Coronary Prevention Study. 
Eur Heart J 2003; 24: 1833-42. 
[43]  Brunzell JD, Hokanson JE. Low-density and high-density lipoprotein 
subspecies and risk for premature coronary artery disease. Am J Med 
1999; 107 (Suppl 2A): 16-8.  
[44]  Stampfer MJ, Krauss RM, Ma J, et al. A prospective study of triglyc-
erides, low-density lipoprotein particle diameter, and risk of myocar-
dial infarction. JAMA 1996; 276: 882-8. 
[45]  Gardner CD, Fortmann SP, Krauss RM. Association of small low-
density  lipoprotein  particles  with  the  incidence  of  coronary  artery 
disease in men and women. JAMA 1996; 276: 875-81. 
[46]  Brousseau ME, O'Connor JJ Jr, Ordovas JM, et al. Cholesteryl ester 
transfer protein TaqI B2B2 genotype is associated with higher HDL 
cholesterol levels and lower risk of coronary heart disease end points 
in  men  with  HDL  deficiency:  Veterans  Affairs  HDL  Cholesterol  
Intervention Trial. Arterioscler Thromb Vasc Biol 2002; 22: 1148- 
54. 
[47]  de Grooth GJ, Zerba KE, Huang S, et al. The cholesteryl ester trans-
fer protein (CETP) TaqIB polymorphism in the Cholesterol and Re-
current  Events  study  (CARE): no  interaction  with  the  response  to 
pravastatin therapy and no effects on cardiovascular outcome. J Am 
Coll Cardiol 2004; 43: 854-7. 
[48]  Liu S, Schmitz C, Stampfer MJ, et al. A prospective study of TaqIB 
polymorphism in the gene coding for cholesteryl ester transfer protein 
and risk of myocardial infarction in middle-aged men. Atherosclero-
sis 2002; 161: 469-74. 
[49]  Borggreve SE, Hillege HL, Wolffenbuttel BH, et al. An increased 
coronary risk is paradoxically associated with common cholesteryl 
ester transfer protein gene variations that relate to higher high-density 
lipoprotein cholesterol: a population-based study. J Clin Endocrinol 
Metab 2006; 91: 3382-8. 
[50]  Blankenberg  S,  Rupprecht  HJ,  Bickel  C,  et  al.  Common  genetic 
variation  of  the  cholesteryl  ester  transfer  protein  gene  strongly  
predicts future cardiovascular death in patients with coronary artery 
disease. J Am Coll Cardiol 2003; 41: 1983-9. 
[51]  Kuivenhoven JA, de Knijff P, Boer JM, et al. Heterogeneity at the 
CETP  gene  locus.  Influence  on  plasma  CETP  concentrations  and 
HDL cholesterol levels. Arterioscler  Thromb  Vasc  Biol  1997; 17: 
560-8. 
[52]  Kondo I, Berg K, Drayna D, Lawn R. DNA polymorphism at the 
locus for human cholesteryl ester transfer protein (CETP) is associ-
ated with high density lipoprotein cholesterol and apolipoprotein lev-
els. Clin Genet 1989; 35: 49-56. 
[53]  Mitchell RJ, Earl L, Williams J, Bisucci T, Gasiamis H. Polymor-
phisms of the gene coding for the cholesteryl ester transfer protein 
and plasma lipid levels in Italian and Greek migrants to Australia. 
Hum Biol 1994; 66: 13-25. 
[54]  Bruce  C,  Sharp  DS,  Tall AR. Relationship of HDL and  coronary 
heart disease to a common amino acid polymorphism in the choles-
teryl  ester  transfer  protein  in  men  with  and  without  hypertriglyc-
eridemia. J Lipid Res 1998; 39: 1071-8. 
[55]  Gudnason V, Thormar K, Humphries SE. Interaction of the choles-
teryl ester transfer protein I405V polymorphism with alcohol con-
sumption in smoking and non-smoking healthy men, and the effect 
on  plasma  HDL  cholesterol  and  apoAI  concentration.  Clin  Genet 
1997; 51: 15-21. 
[56]  Kakko S, Tamminen M, Päivänsalo M, et al. Cholesteryl ester trans-
fer protein gene polymorphisms are associated with carotid athero-
sclerosis in men. Eur J Clin Invest 2000; 30: 18-25. 
[57]  Bang  HO,  Dyerberg J,  Nielsen  AB.  Plasma  lipid  and  lipoprotein 
pattern in Greenlandic West-Coast Eskimos. Lancet 1971; 1: 1143- 
5. 
[58]  Glueck CJ, Gartside P, Fallat RW, Sielski J, Steiner PM. Longevity 
syndromes: Familial hypobeta and familial hyperalpha lipoproteine-
mia. J Lab Clin Med 1976; 88: 941-57. 
[59]  Puca  AA, Daly  MJ,  Brewster  SJ, et al.  A genome-wide  scan  for 
linkage to human exceptional longevity identifies a locus on chromo-
some 4. Proc Natl Acad Sci USA 2001 Aug 28; 98: 10505-8. 
[60]  Barzilai N, Atzmon G, Schechter C, Schaefer EJ, Cupples AL, Lipton 
R, Cheng S, Shuldiner AR. Unique lipoprotein phenotype and geno-
type associated with exceptional longevity. JAMA 2003; 290: 2030-
40.  
 
 
Received: December 21, 2009  Revised: December 25, 2009  Accepted: December 28, 2009 
 
© Kolovou et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/ 
by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the work is properly cited.  